Deutsche Beteiligungs AG

  • ISIN: DE000A1TNUT7
  • Land: Germany

Nachricht vom 23.01.2012 | 16:44

Deutsche Beteiligungs AG: Dividend of 0.80 Euros per share recommended/Consolidated loss of 16.6 million Euros due to unrealised negative valuation movements

Deutsche Beteiligungs AG  / Key word(s): Dividend/Final Results

23.01.2012 16:44

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.


Announcement consistent with § 15 WpHG
Deutsche Beteiligungs AG, WKN 550 810/
ISN DE0005508105

Supervisory Board and Board of Management recommend dividend of 0.80 euros
per share

Surplus dividend following strong realisations / Negative net income of
16.6 million euros

At the upcoming Annual Meeting of Deutsche Beteiligungs AG, the Supervisory
Board and the Board of Management will recommend paying a dividend of 0.40
euros per share in addition to a surplus dividend of 0.40 euros per share,
or a total of 0.80 euros per share for the 2010/2011 financial year (1
November to 31 October). A resolution to that effect was passed today. This
continues the dividend policy Deutsche Beteiligungs AG has been pursuing in
recent years: a base dividend that is geared to net asset value per share
and current money market rates is to be increased by a surplus dividend in
years recording successful realisations from the portfolio. For the
preceding 2009/2010 financial year, a total of 1.40 euros per share (a base
dividend of 0.40 euros and a surplus dividend of 1.00 euro) was paid in
March 2011.

The Supervisory Board of Deutsche Beteiligungs today also approved the
2010/2011 consolidated financial statements and adopted the 2010/2011
separate financial statements of Deutsche Beteiligungs AG. For 2010/2011,
Deutsche Beteiligungs AG posted a consolidated loss of 16.6 million euros.
Net asset value therefore fell to 17.47 euros per share.

The consolidated loss was substantially due to unrealised negative
valuation movements. A prime factor was the price loss of a quoted
investment in the portfolio, Homag Group AG. This investment is valued at
its stock market quotation on the reporting date. The price of Homag shares
dropped from 15.48 euros to 8.48 euros over financial year 2010/2011; this
equates to a negative valuation effect of 18.5 million euros on income.
Deutsche Beteiligungs AG also uses parameters that derive from the stock
market for the valuation of its unquoted investments. The sharp drop in
stock market levels beginning in August 2011 therefore also had a negative
impact on the valuation of the other companies in the portfolio.
The Company's liquidity was not compromised by the consolidated loss. At
the reporting date on 31 October, Deutsche Beteiligungs AG had cash and
securities totalling 155.6 million euros, an increase of 15 million euros
over the preceding year. The rise stems, among other things, from proceeds
from the realisation of Heim & Haus GmbH and the (partial) disinvestment of
Preh GmbH in May and June.
The Company will issue its consolidated financial statements on 26 January

The Board of Management
Frankfurt am Main, 23 January 2012

23.01.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at and

Language:     English
Company:      Deutsche Beteiligungs AG
              Börsenstrasse 1
              60313 Frankfurt am Main
Phone:        +49 (0)69 957 87-01
Fax:          +49 (0)69 957 87-199
ISIN:         DE0005508105
WKN:          550810
Indices:      SDAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
              Freiverkehr in Berlin, Hamburg, München, Stuttgart
End of Announcement                             DGAP News-Service

Anleihe im Fokus

DREF: Investieren in Bildung

Kupon: 4,375 % p.a.
Zeichnungsfrist: 31. März bis 2. April 2015
Anleihe-Rating: Investmentgrade
Listing: Frankfurter Börse (Entry Standard)

GBC-Research im Fokus

CytoTools AG: Verzögerungen in Indien, aber positiver Verlauf in Europa

Die CytoTools AG gab am 4. März 2015 bekannt, dass es bei der Zulassung des Wundheilpräparates DermaPro in Indien zu Verzögerungen kommt. Die für den europäischen Markt bestimmten Indikationen DFU und VLU liefen aber weiterhin planmäßig. GBC-Analyst Cosmin Filker hat mit dem CytoTools-Vorstand Dr. Freyberg über die Entwicklung in Indien, aber auch über den positiven Verlauf der europäischen Zulassung für DermaPro gesprochen.

Aktueller Webcast

ElringKlinger AG

Financial Results 2014

31. März 2015

Aktuelle Research-Studie

Viscom AG

Original-Research: Viscom AG (von getinsight Research GmbH): Kaufen

01. April 2015